Grace Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Grace Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $22.13 million for the year ending 2025.

  • Grace Therapeutics, Inc. showed a decrease of -3.8% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Grace Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on June 23, 2025.
  • XBRL data for this metric is available from 2018 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 9 years of available data (2018 to 2025), Grace Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 244.6%.
  • Historical annual values: Fiscal year 2025: $22.13 million | Fiscal year 2024: $23.01 million | Fiscal year 2023: $27.88 million | Fiscal year 2022: $30.34 million | Fiscal year 2021: $50.94 million | Fiscal year 2020: $14.24 million | Fiscal year 2019: $16.87 million | Fiscal year 2019: $16.87 million | Fiscal year 2018: $6.42 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: